WhatA benchmarking and analytics platform that measures AI models not by price-per-token but by cost-per-correct-output on real-world coding tasks, giving developers actionable data on true cost-effectiveness.
SignalMultiple commenters point out that price-per-token is misleading because cheaper models often require multiple attempts, debugging, and human recovery time — making them more expensive in practice despite lower sticker prices.
Why NowWith 10+ viable coding models at radically different price points, developers can no longer rely on simple benchmark scores or token prices to make rational purchasing decisions — the comparison has become genuinely complex.
MarketEngineering managers and CTOs at AI-adopting companies (500K+ orgs); TAM ~$1B as part of broader AI ops tooling; Artificial Analysis and chatbot-arena exist but don't measure cost-per-correct-output on real tasks.
MoatProprietary dataset of real-world task completions across models, with ground-truth correctness labels, is expensive and slow to build — first mover accumulates an irreplaceable evaluation corpus.
Kimi K2.7-Code: open-source coding model with better token efficiencyView discussion ↗ · Article ↗ · 438 pts · June 12, 2026
More ideas from June 12, 2026
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.